tbuckley/cabot-search huggingface dataset:
Occult chronic septic arthritis due to Proteus mirabilis
Authors: J. G. Hardin
Journal: JAMA (1978)

A MAN with long-standing adult Still's disease<sup>1</sup>had a<i>Proteus mirabilis</i>arthritis of the hip a year following an intra-articular injection of 30 mg of prednisolone tebutate. Despite appropriate antibiotic therapy and no symptoms suggestive of a continued pyarthrosis, he still had the same organism in the hip at successful joint replacement more than six months later. To my knowledge, it has not previously been clearly demonstrated that such infections may follow a protracted course of this relatively benign nature. <h3>Report of a Case</h3> A 36-year-old man had a recurring febrile illness since the age of 18 years, ultimately diagnosed as late-onset Still's disease. In 1971, bilateral hip arthritis was first noted, and his long-standing prednisone therapy was permanently discontinued because of increasing side effects. In March 1975, an attack of pain in the left hip and shoulder was unresponsive to 150 mg/day of indomethacin, and approximately 30 mg
Peripheral entrapment neuropathies
Authors: A. Cracchiolo
Journal: JAMA (1968)

Seventy-three patients were surgically treated for a variety of peripheral entrapment neuropathies. Although the carpal tunnel syndrome was most common, compressions of the ulnar, radial, peroneal, posterior tibial, and suprascapular nerves were also found. In several cases, the entrapment was only a sign of the more generalized systemic disease present.
Highlighting Cancer Chemotherapy Reports
Authors: Jerome Block
Journal: CA A Cancer Journal for Clinicians (1973)

The April issue of Caiicer Chemotherapy Reports cele brates the early summer with notes on a few drugs in the bud stage of development.That is.they are still full of promises and one eagerly awaits their full flowering.Further.one gen uinely hopes that these blooms will prove to he not merely showy annuals, hut rather hardy perennials which will tratis plant well in the gardens of horticulturists other than the ini tial observer.For example, tilorone, as shown by Wanipler.ci al. (Uni-versity of Virginia, Richmond, Virginia) is an interferon in ducing agent which does not depress the bone marrow.Some side features of the agent include stimulation of the phagocy tic response and antibody production.Early clinical studies demonstrated some antitumor effect against melanoma.Over the past year several reports have conic from the Mideast on new methanesulfonic acid esters of aminogly cols.These have demonstrated activity in chronic myelocy tic leitkeniia, and in the current article by Gad-el-Mawla, et al. (Cairo University, Cairo, Egypt) activity against malig nant lymphoma was also seen.Another compound, not as new but with a new dosage, is the progestational compound.6, 17a-dimethyl-6-dehydroprogesterone.17a-dimethyl-6dehydroprogesterone.Malkasian, et al. (Mayo Clinic, Roch ester, Minnesota) notes that large doses of the progesterone, up to 800 mg.daily.were associated with unanticipated clin ical regression of ovarian malignancy which had progressed to radiation resistance and alkylating agent resistance.Cer tainly, if this compound, which has not had such favorable results in smaller dosages.proves to he effective in the mas sive dose program described by the authors, much useful benefit to patients can he anticipated.A clinical trial is reported by Lippman, et al. (Sloan-Ket tering Institute.New York, New York) on cis-platinum diammine dichloride.While the compound is still new, one fears that while platinum may glitter, its potential use as a chemotherapeutic agent in man may he less than gold.The drug.readers will recall, has had striking antitumor activity in murine systems.It produces such toxic effects as myelo suppression.renal functional impairment, high frequency hearing loss, nausea, and vomiting.Several patients experi enced brief therapeutic benefit from the compound.The au thors call for further studies of the agent in combination with
Tuberculous Immigrants
Authors: D. J. P. Gray
Journal: BMJ (1965)

MEDIBCARLJOHNAL 525 foreskin and uterine tissues faecal extracts from erythema infectiosum patients and observed cytopathic effects characterized by rounding of cells and formation of multinucleate giant-cells.This cytopathic agent was labile, as evidenced by the fact that it could not be reisolated from the original specimens after their storage for three weeks at -200 C. We experienced the same lability with our own isolates, which either got lost through storage or contaminated with true simian viruses during subsequent passages in monkey-kidney-cell cultures.In several respects (nature of cytopathic effect, lability, particle diameter of about 100 mmu, absence of haemagglutinin) the agents isolated by us and by Wilcox and Evans from cases of erythema infectiosum (a mild, non- febrile erythematous and maculopapular rash) resemble the respiratory syncytial virus.On the other hand, no viruses bearing any analogy with other aetiologic agents of various exanthems (Coxsackie, E.C.H.O., reo- and adenoviruses) have ever been isolated from unequivocal cases of erythema infec- tiosum.It thus appears as a distinct possibility, in view of all these facts, that the aetio- logic agent of erythema infectiosum may be biologically related to the respiratory syncytial virus, which, as was indicated in your leading article, may itself cause exanthematous disease.The fact that antigenic heterogeneity has been observed among various isolates of respiratory syncytial virus4 5 also suggests that this virus may be a member of a larger group of related agents causing illnesses of varying symptomatology and severity, ranging from mild exanthems to acute respiratorytract infections.
Poetry
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients
Authors: F. K. Port
Journal: JAMA (1993)

<h3>Objective.</h3> —To compare mortality risk among cadaveric renal transplant recipients vs transplant candidates on dialysis in the cyclosporine era. <h3>Setting.</h3> —Patient mortality risk was analyzed by treatment modality for a completed statewide patient population. <h3>Patients.</h3> —All Michigan residents younger than age 65 years who started end-stage renal disease (ESRD) therapy between January 1,1984, and December 31, 1989, were included. Patients were followed up from ESRD onset (n=5020), to wait-listing for renal transplant (n=1569), to receiving a cadaveric first transplant (n=799), and to December 31, 1989. <h3>Main Outcome Measure.</h3> —Mortality rates. <h3>Results.</h3> —Using a time-dependent variable based on the waiting time from date of wait-listing to transplantation and adjusting for age, sex, race, and primary cause of ESRD, the relative risk (RR) of dying was increased early after transplantation and then decreased to a beneficial long-term effect, given survival to 365 days after transplantation (RR, 0.36;<i>P</i>&lt;.001). This lower long-term risk was most pronounced (RR, 0.25) among diabetic transplant recipients compared with diabetic wait-listed dialysis patients (<i>P</i>&lt;.001) and not observed among patients with glomerulonephritis as cause of ESRD (<i>P</i>&gt;.05). Overall, the estimated times from transplantation to equal mortality risk was 117±28 days and to equal cumulative mortality was 325±91 days. <h3>Conclusions.</h3> —The overall mortality risk following renal transplantation was initially increased, but there was a long-term survival benefit compared with similar patients on dialysis. These analyses allow improved description of comparative mortality risks for dialysis and transplant patients and allow advising patients regarding comparative survival outcomes. (<i>JAMA</i>. 1993;270:1339-1343)
Terminology of Antibiotics
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DIAGNOSIS OF TRICHINOSIS.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Small-Molecule XIAP Antagonist Restores Caspase-9-Mediated Apoptosis in XIAP-Positive Diffuse Large B-Cell Lymphoma Cells.
Authors: Saskia A.G.M. Cillessen, John C. Reed, Clemencia Pinilla, Chris J.L.M. Meijer, Erik Hooijberg, Corine J. Hess, Kitty C.M. Castricum, Pim Kortman, Gert J. Ossenkoppele, Joost J. Oudejans
Journal: Blood (2007)
Hospitality for Overseas Visitors
Authors: H. A. Sandford
Journal: BMJ (1948)

All babies admitted to the neonatal unit during a period of 41 months were prospectively studied to find out the incidence, aetiology, and outcome of neonatal pneumonia, and the value of routine cultures of endotracheal tubes. Pneumonia of early onset (before age 48 hours) occurred in 35 babies (incidence 1.79/1000 live births). In 20 (57%) it was caused by group B streptococci. Blood cultures showed the presence of organisms in 16 of the 35 (46%). There were 41 episodes of pneumonia of late onset in 39 babies. Thirty six of the 39 were preterm, and 34 were artificially ventilated (10% of all ventilated babies). Endotracheal tube colonisation had occurred in 94% of these, most commonly by Gram negative organisms and Staphylococcus epidermidis. In only one of seven cases with simultaneous bacteraemia was the same organism grown from cultures of the blood. After controlling for gestational age and duration of artificial ventilation there was no difference in the incidence or timing of endotracheal tube colonisation between babies who did and did not have pneumonia of late onset. Ten babies with pneumonia of early onset (29%) died; all were preterm infants. Only one death (2%) was associated with an episode of pneumonia of late onset. Routine surveillance cultures were not helpful in predicting and managing pneumonia of late onset.
Abstract 167: Inhibition of Endoplasmic Reticulum Stress Improves Vascular Function in Type II Diabetic Mice
Authors: Dustin M Lee, Micah L Battson, Dillon K Jarrell, Shuofei Hou, Kayl Ecton, Christopher L Gentile
Journal: Circulation Research (2017)

Cardiovascular disease is the leading cause of death in the United States with type 2 diabetes (T2D) representing a major risk factor in its development. Vascular dysfunction, characterized by arterial stiffness and endothelial dysfunction occur prior to overt cardiovascular disease and predict future cardiovascular events and mortality in diabetic individuals. Dysfunction of the endoplasmic reticulum (ER), or ER stress, is associated with the development and progression of chronic metabolic diseases such as obesity and T2D. However, the role of ER stress in the development of vascular dysfunction observed in T2D is unclear. We hypothesized that inhibiting ER stress would improve both measures of vascular dysfunction observed in diabetic mice. Male C57BL/6J Leprdb (DB) male mice lacking the leptin receptor were used as a model of T2D. Starting at 4 months of age DB mice were given intraperitoneal injections of ER stress inhibitor, tauroursodeoxycholic acid (TUDCA) at 250mg/kg/day for 4 weeks. C57BL/6J mice were used as controls (n=8 for all groups). Pulse wave velocity (PWV) was measured at baseline (prior to treatment) and after TUDCA treatment. Secondary order mesenteric resistance arteries (MRA) were used to determine endothelial dependent dilation (EDD). DB mice not treated with TUDCA were used for acute studies of EDD by incubating the MRA for 1hr with 0.5mM TUDCA. At baseline, DB mice displayed increased arterial stiffness compared to C57BL/6J controls as measured by PWV (457±25 vs 348±26 cm/s, p&lt;0.05). TUDCA treatment significantly decreased PWV (402±12 cm/s, p&lt;0.05). Both acute and chronic TUDCA treatment improved DB EDD compared to untreated controls (58.4±13.8 and 49.1±6.1%, vs 19.8±9.6%, p&lt;0.05). Expression of ER stress-associated genes CHOP and ATF4 were significantly elevated in DB perivascular adipose tissue and treatment with TUDCA significantly decreased ATF4 compared to DB. In the aorta, TUDCA significantly decreased GRP78 and XBP1 compared to DB. These data support the hypothesis that ER stress contributes to the vascular dysfunction observed in T2D and suggest that ER stress may be a potential target in the treatment of T2D related vascular stiffening and dysfunction.
Reducing adolescent pregnancy through school and community-based education
Authors: M. L. Vincent
Journal: JAMA (1987)

The resident population of the western portion of a South Carolina county has undergone a public health information and education intervention since October 1982. The purpose of the intervention has been to reduce the occurrence of unintended pregnancies among unmarried adolescents. Intervention messages are targeted at parents, teachers, ministers and representatives of churches, community leaders, and children enrolled in the public school system. The messages emphasize development of decision-making and communication skills, self-esteem enhancement, and understanding human reproductive anatomy, physiology, and contraception. The estimated rate of pregnancy ([live births plus fetal deaths plus induced abortions] per 1000 female population) for females aged 14 to 17 years in the county's western portion has declined remarkably since the intervention began, and the changes are statistically significant when compared with three sociodemographically similar counties and also with the eastern portion of the county. (<i>JAMA</i>1987;257:3382-3386)
Let's Be Clear
Authors: Mark L. Rosenberg
Journal: JAMA (1992)

WE have worked for more than 10 years in the US Public Health Service to clarify the patterns of violence through surveillance and research and to identify and evaluate interventions to prevent and reduce the impact of violence. It is time to be clear about what we mean by violence and why we believe that violence is a public health problem. Violence is the intentional use of physical force against another person or against oneself, which either results in or has a high likelihood of resulting in injury or death. Violence includes suicidal acts as well as interpersonal violence such as rape, assault, child abuse, or elder abuse. Fatal violence results in suicides and homicides. The term<i>violence</i>has been used to connote both a subset of behaviors (which produce injuries) and outcomes (ie, the injuries themselves). We use<i>violence</i>to refer to a particular class of behaviors that cause
Penetration injury to the heart. Nine consecutive cases at a community hospital
Authors: J. R. Wilder
Journal: JAMA (1980)

During the past 25 years, great progress has been made in saving patients with serious cardiac injuries. This study is based on nine consecutive cases of penetrating wounds to the heart treated successfully by surgical intervention at a community hospital with no facilities for cardiopulmonary bypass. Early surgery is advocated for patients suspected of having penetrating injury of the heart. (<i>JAMA</i>244:2080-2081, 1980)
In vitro and in vivo characterization of VIR-2218, an investigational RNAi therapeutic targeting hepatitis B virus
Authors: Yesseinia Anglero-Rodriguez, Florian Lempp, Abigail Liebow, Tuyen Nguyen, Sarah LeBlanc, Charalambos Kaittanis, Joseph Barry, Adam Castoreno, Jonathan Gall, Hannah Kaiser, Christy Hebner, Stuart Milstein, Vasant Jadhav, Anna Bakardjiev
Journal: Journal of Hepatology (2020)
Coombs' (Antiglobulin) Reaction in Severely Burned Rats-M. D. McCarthy and M. D. McCarthy
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mismatched blood
Authors: A. R. Holder
Journal: JAMA (1974)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase I study of TRC105 (anti-CD105 monoclonal antibody) in metastatic castration-resistant prostate cancer (mCRPC).
Authors: D. Adelberg, A. B. Apolo, R. A. Madan, J. L. Gulley, A. Pierpoint, D. R. Kohler, J. B. Trepel, S. M. Steinberg, D. Price, B. R. Leigh, C. P. Theuer, W. D. Figg, W. L. Dahut
Journal: Journal of Clinical Oncology (2011)

e15070 Background: TRC105 is a human/murine chimeric IgG1 monoclonal antibody to CD105 (endoglin) that inhibits angiogenesis and tumor growth through inhibition of endothelial cell (EC) proliferation, antibody−dependent cellular cytotoxicity and induction of apoptosis. CD105 is highly expressed on proliferating vascular ECs. Preclinical and clinical evidence demonstrates an important role for angiogenesis in mCRPC biology. Methods: The primary objective is to evaluate safety and identify the maximum tolerable dose of TRC105. Secondary objectives include the assessment of TRC105 pharmacokinetics, PSA response rate and overall response rate (ORR). Eligibility requires ECOG performance status (PS) ≤ 2 and progressive mCRPC. Three cohorts of 3-6 patients receive TRC105 at doses of 1, 3 or 10 mg/kg IV over 1−4 hours every 2 weeks of a 4 -week cycle. Premedications are dexamethasone, acetaminophen, famotidine, and diphenhydramine. PSA is evaluated prior to each treatment and response is assessed every 2 cycles with imaging studies. Results: Nine patients are enrolled in cohorts 1−3. Median age is 66 (range 47−84), ECOG PS 1 (1−2), Gleason score 8 (6−10), on−study PSA 231 (0.14 – 2923), and number of prior therapies after gonadotropin-releasing hormone agonist or anti−androgen therapy 3 (0−6). Median time on study is 16 weeks (8 – 28). Dose-limiting toxicity was not observed. Grade 1 to 2 infusion reactions occurred in 5 patients. PSA declines were seen in two of three patients in cohort 3 (17 and 59% from baseline); each had progressed on docetaxel and at least one second−line agent. Six of 8 evaluable patients with measurable soft tissue disease achieved stable disease (1 in cohort 1, 2 in cohort 2 and 3 in cohort 3); one patient in cohort 3 remains on study (8 weeks). Conclusions: TRC105 is tolerated at doses up to 10 mg/kg every 2 weeks with early evidence of clinical activity in patients with mCRPC. Accrual is ongoing to evaluate higher doses and more frequent dosing.